Calprotectin as a diagnostic tool for inﬂammatory bowel diseases (Review)

Chatzikonstantinou,Marianthi; Konstantopoulos,Panagiotis; Stergiopoulos,Spyros; Kontzoglou,Konstantinos; Verikokos,Christos; Perrea,Despina; Dimitroulis,Dimitris

doi:10.3892/br.2016.751

Calprotectin as a diagnostic tool for inﬂammatory bowel diseases (Review)

Authors:
- Marianthi Chatzikonstantinou
- Panagiotis Konstantopoulos
- Spyros Stergiopoulos
- Konstantinos Kontzoglou
- Christos Verikokos
- Despina Perrea
- Dimitris Dimitroulis
View Affiliations

Affiliations: Laboratory of Experimental Surgery and Surgical Research N.S Christeas, National and Kapodistrian University of Athens, Athens 11527, Greece, Fourth Department of Surgery, Athens University Medical School, Attikon University Hospital, Athens 12462, Greece, Second Department of Propedeutic Surgery, ‘Laiko’ General Hospital, National and Kapodistrian University of Athens, Medical School, Athens 11527, Greece
Published online on: September 7, 2016 https://doi.org/10.3892/br.2016.751
Pages: 403-407

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammatory bowel diseases (IBD) are chronic intestinal disorders caused by a number of factors, including external influences, intestinal microbiota and genetics. The two major clinically defined types of IBD are Crohn's disease and ulcerative colitis, each of which is characterized by relapses in the clinical course, thus patients must be under constant observation via regular endoscopies. As endoscopy, which has been used for direct evaluation and diagnosis of IBD, requires uncomfortable and expensive bowel preparation, a non‑invasive test was required to reduce the number of patients undergoing unnecessary endoscopy. Calprotectin is a protein occurring in the cytosol of inflammatory cells and is released by the activation of leukocytes. As it is elevated and stable in the faeces of patients with IBD and can be reliably detected in faecal samples of <5 g, it may serve as an inexpensive, non‑invasive diagnostic method for IBD. This is explored in the following review.

View Figures

View References

1	Fagerhol MK, Dale I and Andersson T: A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 16:273–282. 1980.PubMed/NCBI
2	Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P and Fagerhol MK: Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 336:763–765. 1990. View Article : Google Scholar : PubMed/NCBI
3	Sohnle PG, Collins-Lech C and Wiessner JH: Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils. J Infect Dis. 163:187–192. 1991. View Article : Google Scholar : PubMed/NCBI
4	Røseth AG, Schmidt PN and Fagerhol MK: Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 34:50–54. 1999. View Article : Google Scholar : PubMed/NCBI
5	Fagerhol MK, Andersson KB, Andresen CF Naess, Brandtzaeg P and Dale I: Calprotectin (the L1 leucoyte protein)Stimulus Response Coupling: The Role of Intracellular Calcium Binding Proteins. Smith VL and Dedman JR: CRC Press Inc.; Boca Raton, FL: pp. 187–210. 1990
6	Gaya DR and Mackenzie JF: Faecal calprotectin: A bright future for assessing diseaseactivity in Crohn's disease. QJM. 95:557–558. 2002. View Article : Google Scholar : PubMed/NCBI
7	Yiu S, Mikami M and Yamazaki M: Induction of apoptoic cell death in mouse lymphoma and human leukaemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. J Leukoc Biol. 336:763–765. 1995.
8	Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF and Dale I: Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 50:113–123. 1997. View Article : Google Scholar : PubMed/NCBI
9	Røseth AG, Fagerhol MK, Aadland E and Schjønsby H: Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 27:793–798. 1992. View Article : Google Scholar : PubMed/NCBI
10	Lasson A, Kilander A and Stotzer PO: Diagnostic yield of colonoscopy based on symptoms. Scand J Gastroenterol. 43:356–362. 2008. View Article : Google Scholar : PubMed/NCBI
11	Bunn SK, Bisset WM, Main MJ and Golden BE: Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 32:171–177. 2001. View Article : Google Scholar : PubMed/NCBI
12	Røseth AG, Kristinsson J, Fagerhol MK, Schjønsby H, Aadland E, Nygaard K and Roald B: Faecal calprotectin: A novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 28:1073–1076. 1993. View Article : Google Scholar : PubMed/NCBI
13	Meling TR, Aabakken L, Røseth A and Osnes M: Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 31:339–344. 1996. View Article : Google Scholar : PubMed/NCBI
14	Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A and Bjarnason I: High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 45:362–366. 1999. View Article : Google Scholar : PubMed/NCBI
15	Kaser A, Zeissig S and Blumberg RS: Inflammatory bowel disease. Annu Rev Immunol. 28:573–621. 2010. View Article : Google Scholar : PubMed/NCBI
16	Riley SA, Mani V, Goodman MJ, Dutt S and Herd ME: Microscopic activity in ulcerative colitis: What does it mean? Gut. 32:174–178. 1991. View Article : Google Scholar : PubMed/NCBI
17	Barton JR, Gillon S and Ferguson A: Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three-fold rise in Crohn's disease. Gut. 30:618–622. 1989. View Article : Google Scholar : PubMed/NCBI
18	Armitage E, Drummond H, Ghosh S and Ferguson A: Incidence of juvenile-onset Crohn's disease in Scotland. Lancet. 353:1496–1497. 1999. View Article : Google Scholar : PubMed/NCBI
19	Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG and Persson T: Canadian Inflammatory Bowel Disease Study Group: Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology. 110:45–51. 1996. View Article : Google Scholar : PubMed/NCBI
20	Rutgeerts PJ: Prevention of early recurrence of Crohn's disease after ileal resection with ileocolic anastomosis. Eur J Gastroenterol Hepatol. 6:113–116. 1994. View Article : Google Scholar
21	Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M and Kontula K: Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 12:3668–3672. 2006. View Article : Google Scholar : PubMed/NCBI
22	Tsironi E, Feakins RM, Probert CS, Rampton DS and Phil D: Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom. Am J Gastroenterol. 99:1749–1755. 2004. View Article : Google Scholar : PubMed/NCBI
23	Thia KT, Loftus EV Jr, Sandborn WJ and Yang SK: An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 103:3167–3182. 2008. View Article : Google Scholar : PubMed/NCBI
24	Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC and Horak I: Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 75:253–261. 1993. View Article : Google Scholar : PubMed/NCBI
25	Kühn R, Löhler J, Rennick D, Rajewsky K and Muller W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 75:263–274. 1993. View Article : Google Scholar : PubMed/NCBI
26	Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK and Tonegawa S: Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 75:274–282. 1993. View Article : Google Scholar : PubMed/NCBI
27	Gregersen PK and Olsson LM: Recent advances in the genetics of autoimmune disease. Annu Rev Immunol. 27:363–391. 2009. View Article : Google Scholar : PubMed/NCBI
28	Peterson DA, Frank DN, Pace NR and Gordon JI: Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe. 3:417–427. 2008. View Article : Google Scholar : PubMed/NCBI
29	Ristvedt SL, McFarland EG, Weinstock LB and Thyssen EP: Patient preferences for CT colonography, conventional colonoscopy, and bowel preparation. Am J Gastroenterol. 98:578–585. 2003. View Article : Google Scholar : PubMed/NCBI
30	Røseth AG, Aadland E, Jahnsen J and Raknerud N: Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 58:176–180. 1997. View Article : Google Scholar : PubMed/NCBI
31	Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M and Bjarnason I: A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 47:506–513. 2000. View Article : Google Scholar : PubMed/NCBI
32	Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S and Maltinti G: Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 35:642–647. 2003. View Article : Google Scholar : PubMed/NCBI
33	van Rheenen PF, Van de Vijver E and Fidler V: Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ. 341:c33692010. View Article : Google Scholar : PubMed/NCBI
34	von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, Paraskeva P and Tekkis PP: Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 102:803–813. 2007. View Article : Google Scholar : PubMed/NCBI
35	Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ and Zinsmeister AR: Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 95:2831–2837. 2000. View Article : Google Scholar : PubMed/NCBI
36	Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S and Bottai M: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 54:364–368. 2005. View Article : Google Scholar : PubMed/NCBI
37	Røseth AG, Aadland E and Grzyb K: Normalization of faecal calprotectin: A predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 39:1017–1020. 2004. View Article : Google Scholar : PubMed/NCBI
38	Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S and Golden BE: Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 33:14–22. 2001. View Article : Google Scholar : PubMed/NCBI
39	Fireman Z, Mahajna E, Broide E, Shapiro M, Fich L, Sternberg A, Kopelman Y and Scapa E: Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut. 52:390–392. 2003. View Article : Google Scholar : PubMed/NCBI
40	Crama-Bohbouth G, Pena AS, Biemond I, Verspaget HW, Blok D, Arndt JW, Weterman IT, Pauwels EK and Lamers CB: Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut. 30:1236–1240. 1989. View Article : Google Scholar : PubMed/NCBI
41	Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP and Rene E: Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology. 98:811–818. 1990.
42	Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY and Modigliani R: Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut. 35:231–235. 1994.
43	Biancone L, De Nigris F, Del Vecchio Blanco G, Monteleone I, Vavassori P, Geremia A and Pallone F: Review article: Monitoring the activity of Crohn's disease. Aliment Pharmacol Ther. 16 Suppl 4:29–33. 2002. View Article : Google Scholar : PubMed/NCBI
44	Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK and Bjarnason I: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 119:15–22. 2000. View Article : Google Scholar : PubMed/NCBI
45	Modigliani R: Endoscopic management of inflammatory bowel disease. Am J Gastroenterol. 89:S53–S65. 1994.PubMed/NCBI